In these cases, all patients maintained glycaemic control, with HbA1c levels remaining below 7.5%
Still, for wellness clinics and functional-medicine providers, custom formulations hint at GLP-1s longer-term potential in longevity and metabolic optimizationan arena branded drugmakers cant legally market toward
It's about winning the mental game, which, as we've seen with countless clients, is often the biggest battle
* For more information about this side effect, see the Side effect focus section below
Your appetite is highly suppressed, right
The percentage of patients prescribed a GLP-1 drug with both an overweight or obesity diagnosis and a type 2 diabetes diagnosis increased 17.4 percent (rising from 30.4 percent in 2019 to 35.7 percent in 2024)